Next Generation Sequencing

Next Generation Sequencing Market Outlook

The global Next Generation Sequencing (NGS) market is projected to reach approximately USD 30 billion by 2035, with a robust compound annual growth rate (CAGR) of around 20% from 2025 to 2035. The increasing demand for personalized medicine, advancements in technology, and the declining cost of sequencing are the key growth factors driving this expansion. Additionally, the growing prevalence of genetic disorders and the rising focus on genomics research across various fields including oncology, microbiology, and agriculture are contributing to the market's growth trajectory. Furthermore, the integration of NGS technologies with artificial intelligence and machine learning is expected to innovate data analysis processes and enhance precision in results. These developments are not only pushing the boundaries of genetic research but also making it more accessible and affordable for institutions and healthcare providers alike.

Growth Factor of the Market

One of the primary growth factors for the Next Generation Sequencing market is the rapid advancements in sequencing technologies that enhance throughput and reduce costs. Innovations such as high-throughput sequencing and improved bioinformatics tools are facilitating faster data processing and analysis, making genomic research more efficient. Furthermore, the increasing application of NGS in various fields like oncology, rare genetic disorders, and infectious diseases is expanding its usage beyond traditional genomics research. The demand for personalized medicine, which tailors treatment based on an individual's genetic makeup, is also driving growth, as healthcare providers look to NGS for insights into patient care. Additionally, government initiatives and funding aimed at promoting genomic research further bolster market growth, creating a favorable environment for NGS technologies to thrive.

Key Highlights of the Market

• The NGS market is expected to witness a CAGR of 20% from 2025 to 2035.
• Advancements in sequencing technologies are significantly reducing the cost of sequencing.
• Personalized medicine is becoming increasingly reliant on genomic and molecular analysis.
• Government funding and initiatives are enhancing research capabilities in genomics.
• The integration of AI and machine learning is revolutionizing data analysis methods in NGS.

By Product Type

Consumables:

The consumables segment is a vital part of the Next Generation Sequencing market, encompassing reagents, sample preparation kits, and other necessary materials used in the sequencing process. This segment is experiencing significant growth, driven by the increasing volume of sequencing activities and the demand for high-quality data in research and clinical applications. As the frequency of sequencing continues to rise, especially in areas such as personalized medicine and oncology, the need for consumables is expected to grow alongside it. Innovations in consumable products, such as improved reagents that yield higher-quality results or faster sample preparation kits, are further propelling this segment. The continuous development of customized solutions tailored to specific applications also enhances the attractiveness of consumables in the market.

Platforms:

The platforms segment, which includes sequencing instruments and devices, is crucial for the NGS market's growth as it represents the technological backbone of sequencing processes. With various platforms available on the market, including those based on sequencing by synthesis and other innovative technologies, research institutions and clinical laboratories can select systems that best fit their specific needs. The evolution of sequencing platforms has led to improved accuracy, speed, and cost-effectiveness. As institutions invest in cutting-edge technologies to remain competitive and explore new areas of genomics research, the demand for high-performance sequencing platforms is expected to rise significantly over the forecast period. Furthermore, technological advancements that facilitate the miniaturization of sequencing devices and enhance user-friendliness are likely to attract more users, increasing market penetration.

Services:

The services segment encompasses a wide range of offerings including sequencing services, data analysis, and bioinformatics. As the NGS market expands, the demand for expert services that support the interpretation of complex genomic data is growing. Organizations often lack the in-house expertise to analyze and interpret sequencing data effectively, leading to a reliance on specialized service providers. This trend is particularly pronounced in clinical settings, where accurate data interpretation is critical for patient care decisions. Moreover, the emergence of new research areas, such as metagenomics and transcriptomics, is creating opportunities for service providers to offer tailored solutions that meet the evolving needs of researchers and healthcare professionals. The continued evolution in bioinformatics tools and platforms further enhances the value of services, making them integral to the NGS ecosystem.

By Application

Diagnostics:

The diagnostics segment is one of the most prominent applications of Next Generation Sequencing, driven by the demand for accurate and early detection of diseases. NGS enables comprehensive genomic profiling, which is essential for identifying genetic mutations associated with various conditions, including cancer and rare genetic disorders. With the increasing emphasis on precision medicine, diagnostic applications are rapidly adopting NGS technologies to provide more personalized treatment options. Furthermore, the ability to analyze multiple genes simultaneously allows for more thorough investigations of complex diseases, enabling healthcare providers to develop targeted therapies. As regulatory frameworks evolve to support the clinical integration of NGS, the diagnostics segment is expected to experience substantial growth, leading to improved patient outcomes and more effective treatment strategies.

Drug Discovery:

In drug discovery, the application of Next Generation Sequencing is transforming the way new therapies are developed. By providing insights into the genetic basis of diseases, NGS enables researchers to identify novel drug targets and understand the mechanisms of action for existing therapies. This application is particularly valuable in oncology, where genomic data can inform the development of targeted therapies that address specific mutations. Moreover, NGS technologies facilitate the screening of large libraries of compounds against genetic targets, significantly accelerating the drug discovery process. As pharmaceutical companies continue to seek more efficient pathways to bring drugs to market, the integration of NGS into their R&D processes is likely to expand, ultimately leading to faster and more effective treatments for patients.

Precision Medicine:

Precision medicine is a rapidly growing application of Next Generation Sequencing, emphasizing the customization of healthcare based on individual genetic profiles. NGS plays a vital role in the development of precision medicine by enabling comprehensive genomic analysis, allowing healthcare providers to tailor treatment plans according to a patient's unique genetic makeup. This approach not only improves treatment efficacy but also minimizes the risk of adverse effects associated with standard therapies. With the increasing adoption of genomic testing and the proliferation of biobanks, the precision medicine segment is expected to gain significant traction in the coming years. As healthcare systems and providers embrace data-driven decision-making, NGS will be pivotal in advancing the field of precision medicine.

Agriculture and Animal Research:

Next Generation Sequencing is also making significant strides in agriculture and animal research, contributing to the development of more resilient crops and healthier livestock. By leveraging NGS technologies, researchers can analyze the genomes of various plant and animal species, identifying traits associated with disease resistance, yield improvement, and environmental adaptability. This genomic information is vital for breeding programs aimed at enhancing agricultural productivity and sustainability. Additionally, NGS aids in understanding the genetic basis of diseases in livestock, facilitating the development of targeted interventions to improve animal health. As the global population continues to grow, the pressure to enhance food production will drive the demand for NGS applications in agriculture and animal research.

By Technology

Sequencing by Synthesis:

Sequencing by synthesis (SBS) is one of the most widely used technologies in Next Generation Sequencing, offering high-throughput capabilities and accurate results. This technology involves the incorporation of fluorescently labeled nucleotides during DNA synthesis, allowing for real-time detection of nucleotide sequences. SBS platforms have gained popularity due to their ability to sequence millions of fragments simultaneously, significantly increasing throughput compared to traditional methods. Additionally, continuous advancements in SBS chemistry and instrumentation are improving the accuracy and efficiency of sequencing processes. As a result, SBS remains a preferred choice for many laboratories and research institutions, driving its substantial growth within the NGS market.

Ion Semiconductor Sequencing:

Ion semiconductor sequencing technology is known for its rapid turnaround times and cost-effective sequencing capabilities. This innovative approach relies on detecting changes in pH that occur during DNA synthesis, enabling real-time sequencing without the need for fluorescent labels. Ion semiconductor sequencing is particularly well-suited for applications requiring quick results, such as clinical diagnostics and infectious disease research. Its scalability and ease of use have made it attractive to both small laboratories and large-scale sequencing facilities. As the demand for faster sequencing solutions increases, this technology is expected to play a significant role in the NGS landscape, catering to a variety of applications.

Single-Molecule Real-Time Sequencing:

Single-molecule real-time (SMRT) sequencing technology offers a unique approach to Next Generation Sequencing by directly observing DNA polymerase activity in real-time. This technology allows for the sequencing of long DNA fragments, which is particularly useful for analyzing complex genomes and structural variants. SMRT sequencing is gaining traction in research areas such as metagenomics and epigenomics, where understanding the complete picture of genomic information is essential. The ability to generate high-quality long reads sets SMRT apart from other sequencing technologies, making it a valuable tool for researchers seeking comprehensive genomic insights. As the applications of long-read sequencing continue to expand, SMRT technology is expected to contribute significantly to the evolution of genomics research.

Nanopore Sequencing:

Nanopore sequencing technology is at the forefront of innovation in the Next Generation Sequencing market, known for its ability to deliver real-time sequencing data with minimal sample preparation. This technology utilizes nanopores to measure changes in ionic current as single DNA or RNA molecules pass through the pore, allowing for direct and rapid sequencing of nucleic acids. The advantages of nanopore sequencing include its portability, long read lengths, and the ability to sequence native DNA without amplification, which preserves the original modifications. These features make nanopore sequencing particularly appealing for field-based applications, environmental monitoring, and clinical diagnostics. As researchers increasingly seek flexible and efficient sequencing solutions, nanopore technology is poised to gain a larger share of the market.

By End User

Academic & Research Institutes:

Academic and research institutes are significant end-users in the Next Generation Sequencing market, driving innovation and exploration in genomics. These institutions utilize NGS technologies for a range of applications, including fundamental research, disease characterization, and the exploration of genetic variation among populations. The ongoing research in areas such as personalized medicine, evolutionary biology, and environmental genomics relies heavily on NGS capabilities to generate accurate and comprehensive genomic data. As funding for genomics research continues to grow, these institutes are expected to invest in advanced sequencing technologies, further stimulating the NGS market. The collaboration between academic institutions and industry partners also enhances the translation of research findings into practical applications, fostering the development of new therapies and solutions.

Pharmaceutical & Biotechnology Companies:

Pharmaceutical and biotechnology companies are increasingly integrating Next Generation Sequencing into their research and development processes to accelerate drug discovery and improve therapeutic outcomes. NGS provides critical insights into the genetic mechanisms underlying diseases, enabling these companies to develop targeted therapies and precision medicine approaches. The use of genomic data in clinical trials enhances patient stratification and improves the likelihood of treatment success. Furthermore, the ability to analyze large genomic datasets allows pharmaceutical firms to identify potential drug candidates and biomarkers more efficiently. As the biopharmaceutical industry continues to evolve towards personalized treatments, the demand for NGS technologies within this segment is expected to rise significantly, driving innovation and competitive advantage.

Hospitals & Clinics:

Hospitals and clinics represent a growing segment of end users in the Next Generation Sequencing market, particularly as genomic testing becomes more integrated into standard clinical practice. The application of NGS in diagnostics and personalized medicine is revolutionizing patient care, providing healthcare providers with valuable information that informs treatment decisions. Hospitals are increasingly adopting NGS for oncology, hereditary disease screening, and infectious disease identification, leading to improved patient outcomes and more precise therapies. As the cost of sequencing continues to decline, more healthcare facilities are likely to invest in NGS capabilities, ensuring that patients have access to cutting-edge genomic testing that can guide their treatment pathways. This trend contributes to the overall growth of the NGS market, as healthcare providers seek to leverage technology to enhance patient care.

By Region

In the North American region, the Next Generation Sequencing market is anticipated to dominate, accounting for nearly 40% of the global market share by 2035. The presence of advanced healthcare infrastructure, coupled with significant investments in genomics research, drives the growth of NGS in this region. Moreover, the increasing incidence of genetic disorders and the rising adoption of personalized medicine contribute to the strong demand for NGS technologies in North America. It is expected that this region will experience a CAGR of around 19% during the forecast period, underscoring its pivotal role in the NGS landscape.

In Europe, the NGS market is also poised for substantial growth, as European countries continue to invest heavily in genomics research and infrastructure development. The increasing emphasis on precision medicine and the rising number of initiatives promoting genomic health are key factors driving market expansion in this region. By 2035, Europe is projected to hold approximately 30% of the global market share for NGS. The collaborative efforts between public and private sectors to advance genomics research and the establishment of biobanks for genetic studies further enhance the growth potential of the NGS market in Europe. Other regions, such as Asia Pacific and Latin America, are also witnessing growing interest in NGS technologies, but their market shares remain comparatively smaller.

Opportunities

The Next Generation Sequencing market is ripe with opportunities, particularly in the context of personalized medicine. As advancements in genomics continue to unfold, there is a growing demand for NGS capabilities that can deliver tailored treatment plans based on individual genetic profiles. This presents a unique opportunity for companies to develop innovative sequencing solutions that cater to the specific needs of healthcare providers and patients. Additionally, the increasing accessibility of sequencing technologies to smaller laboratories and institutions creates a broader market for NGS applications across various sectors, including clinical diagnostics and research. Companies that can leverage these opportunities to introduce cost-effective and efficient NGS solutions will likely gain a competitive edge in the market.

Another significant opportunity lies in the integration of artificial intelligence and machine learning with Next Generation Sequencing technologies. These advancements can improve data analysis, enhance interpretation accuracy, and streamline workflows in genomic research and clinical applications. By harnessing AI-driven tools, researchers and healthcare providers can accelerate the discovery of new biomarkers, improve patient stratification in clinical trials, and enhance overall genomic data analysis. Furthermore, as regulatory frameworks evolve to support the use of NGS in clinical settings, the potential for market growth expands, leading to increased investment in NGS technologies and services. Organizations that can proactively adapt to these trends are well-positioned to capitalize on the opportunities presented by the evolving NGS landscape.

Threats

Despite the promising growth of the Next Generation Sequencing market, several threats could impede its progress. One of the primary concerns is the regulatory landscape, which can significantly affect the adoption and integration of NGS technologies in clinical practices. The complexity and variability of regulatory guidelines across regions can create challenges for companies seeking to bring NGS products to market. Additionally, the evolving nature of genetic data privacy and ethical considerations surrounding genomic testing pose potential threats to the industry. As public awareness regarding genetic privacy grows, companies must navigate these concerns carefully to maintain consumer trust and ensure compliance with regulatory requirements. Failure to address these issues could hinder the market's expansion and slow down the widespread adoption of NGS technologies.

Another threat facing the Next Generation Sequencing market is the intense competition among established players and new entrants. With numerous companies vying for market share, there is a risk of price wars, which could lead to reduced profit margins for NGS providers. Moreover, the rapid pace of technological advancements means that companies must continuously innovate to remain competitive, requiring substantial investment in research and development. Organizations that fail to keep up with technological trends or adequately differentiate their offerings may struggle to capture market share, leading to stagnation or decline. The combination of regulatory challenges and competitive pressures highlights the need for companies to adopt agile strategies and innovative solutions to navigate potential threats effectively.

Competitor Outlook

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• BGI Genomics Co., Ltd.
• Pacific Biosciences of California, Inc.
• Roche Sequencing Solutions, Inc.
• Oxford Nanopore Technologies Limited
• Qiagen N.V.
• Agilent Technologies, Inc.
• Daniel A. Berg, Inc. (DAB)
• Genomatix Software GmbH
• Genomic Health, Inc.
• Exact Sciences Corporation
• MedGenome Inc.
• Zymo Research Corporation
• Grail, Inc.

The competitive landscape of the Next Generation Sequencing market is characterized by the presence of numerous established players and emerging companies, all striving to innovate and capture market share. Illumina, Inc. remains a market leader, known for its cutting-edge sequencing platforms and extensive range of consumables. The company’s consistent investment in research and development, alongside strategic partnerships, has positioned it favorably within the industry. On the other hand, Thermo Fisher Scientific Inc. has also made significant strides in the NGS space, offering a comprehensive suite of products that cater to various applications, from clinical diagnostics to basic research. The company's focus on integrating NGS technologies with their existing portfolio of life science tools further enhances its competitive advantage.

Emerging companies such as Oxford Nanopore Technologies and Pacific Biosciences of California are challenging traditional market leaders by introducing innovative sequencing technologies that deliver unique advantages. Oxford Nanopore's real-time sequencing capabilities, combined with its portability, are appealing for diverse applications, while Pacific Biosciences’ long-read sequencing technology allows for more comprehensive genomic analyses. These companies are rapidly gaining traction in the market as researchers seek more flexible and efficient sequencing solutions. Furthermore, BGI Genomics Co., Ltd. has positioned itself as a significant player by offering cost-effective sequencing services and products, catering to a broader user base, especially in emerging markets.

As the industry continues to evolve, companies are also focusing on strategic mergers and acquisitions to strengthen their market positions and expand their product offerings. For instance, the collaboration between Roche Sequencing Solutions and various research institutions emphasizes the importance of partnerships in driving innovation and advancing NGS applications. Additionally, the increasing emphasis on bioinformatics and data analysis capabilities among competitors highlights the need for comprehensive solutions that integrate sequencing technologies with advanced analytical tools. Overall, the competitive landscape of the Next Generation Sequencing market will likely remain dynamic, characterized by continuous innovation, strategic collaborations, and a focus on meeting the evolving needs of customers.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Grail, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Illumina, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 MedGenome Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Genomic Health, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 BGI Genomics Co., Ltd.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Genomatix Software GmbH
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Zymo Research Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Agilent Technologies, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Daniel A. Berg, Inc. (DAB)
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Exact Sciences Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Roche Sequencing Solutions, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Oxford Nanopore Technologies Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Pacific Biosciences of California, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Next Generation Sequencing Market, By End User
    • 6.1.1 Academic & Research Institutes
    • 6.1.2 Pharmaceutical & Biotechnology Companies
    • 6.1.3 Hospitals & Clinics
    • 6.1.4 Other End Users
  • 6.2 Next Generation Sequencing Market, By Technology
    • 6.2.1 Sequencing by Synthesis
    • 6.2.2 Ion Semiconductor Sequencing
    • 6.2.3 Single-Molecule Real-Time Sequencing
    • 6.2.4 Nanopore Sequencing
    • 6.2.5 Other Technologies
  • 6.3 Next Generation Sequencing Market, By Application
    • 6.3.1 Diagnostics
    • 6.3.2 Drug Discovery
    • 6.3.3 Precision Medicine
    • 6.3.4 Agriculture and Animal Research
    • 6.3.5 Other Applications
  • 6.4 Next Generation Sequencing Market, By Product Type
    • 6.4.1 Consumables
    • 6.4.2 Platforms
    • 6.4.3 Services

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Next Generation Sequencing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Next Generation Sequencing market is categorized based on

By Product Type

• Consumables
• Platforms
• Services

By Application

• Diagnostics
• Drug Discovery
• Precision Medicine
• Agriculture and Animal Research
• Other Applications

By Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single-Molecule Real-Time Sequencing
• Nanopore Sequencing
• Other Technologies

By End User

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Other End Users

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• BGI Genomics Co., Ltd.
• Pacific Biosciences of California, Inc.
• Roche Sequencing Solutions, Inc.
• Oxford Nanopore Technologies Limited
• Qiagen N.V.
• Agilent Technologies, Inc.
• Daniel A. Berg, Inc. (DAB)
• Genomatix Software GmbH
• Genomic Health, Inc.
• Exact Sciences Corporation
• MedGenome Inc.
• Zymo Research Corporation
• Grail, Inc.